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RAPID COMMUNICATION 
Donor and Recipient Leukocytes in Organ Allografts of 
Recipients With Variable Donor-Specific Tolerance: 
With Particular Reference to Chronic Rejection 
Naoya Ichikawa, ,. Anthony]. Demetris, t Thomas E. Starzl, " Qing Ye, ,. 
Toyokazu Okuda, .. Hyo-Jin Chun, t Kaihong Liu, ,. Young-Myeong Kim, ,. 
and Noriko Murase" 
We have attributed organ engraftment to clonal exhaus-
tion-deletion of host-versus-graft and graft-versus-host re-
actions that are reciprocally induced and governed by 
migratory donor and recipient leukocytes. The so-called 
donor passenger leukocytes that migrate from the allo-
graft into the recipients have been thoroughly studied 
(chimerism), but not the donor leukocytes that remain in, 
or return to, the transplanted organ. Therefore, using flow 
cytometry we determined the percentage and lineages of 
donor leukocytes in cell suspensions prepared from Lewis 
(LEW) cardiac allografts to 100 days posnransplantation. 
The LEW hearts were transplanted to naIve untreated 
Brown Norway (BN) recipients (group 2), to naIve BN 
recipients treated with a 28-day or continuous course of 
tacrolimus (TAC) (groups 3 and 4), and to drug-free BN 
recipients pretolerized by earlier bone marrow cell (BMC) 
or orthotopic LEW liver transplantation (groups 5 and 6). 
The findings in the heart cell suspensions were correlated 
with the results from parallel histopathologic-immunocy-
tochemical studies and other studies of the grafts and of 
host tissues. Although the LEW heart allografts were re-
jected in 9.6 days by the unmodified recipients of group 2, 
all beat for 100 days in the recipients of groups 3 through 
6. Nevertheless, all of the long-surviving cardiac allografts 
(but not the isografts in group 1) were the targets of an 
immune reaction at 5 days, reflected by dramatic increases 
in the ratio of leukocytes to nouleukocyte nucleated cells 
from normal values of 1:5-1:6 to 1:1-5:1 and by manifold 
other evidence of a major inflammatory event. The acute 
changes returned to baseline by 100 days in the chronic 
rejection (CR) free hearts of groups 4 and 6, but not in the 
CR-afHicted hearts of short-course TAC group 3 or the 
less-severely damaged hearts of the BMC-prime group 5. 
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The freedom from CR in groups 4 and 6 was associated 
with a large donor contribution to the intracardiac leuko-
cyte population at 5 days (28.6% and 22% in the respec-
tive groups) and at 100 days (30.5% in group 4 and 8.4% 
in group 6) compared with 2% and 1.2% at 100 days in 
the CR-blighted allografts of the partially tolerant animals 
of groups 3 and 5. Whether large or small, the donor 
leukocyte fraction always included a subset of class II 
leukocytes that had histopathologic features of dendritic 
cells. These class 11+ cells were of mixed myeloid (CDll-
b/c+) and lymphoid lineages; their migration was mark-
edly inhibited by TAC and accelerated by donor-specific 
priming and TAC discontinuance. Although a large donor 
leukocyte population and a normalleukocytel nonleuko-
cyte cell ratio were associated with freedom from CR, 
these findings and the lineage profile of the intrac~ ",Hac 
leukocytes were not associated with tolerance in 'he ~ili­
mals of groups 3 and 4 under active TAC treatn. The 
findings in this study, singly and in their entire 
compatible with our previously proposed leuk, 
migration-localization paradigm of organ allograft aCL .. 
tance and tolerance. (Liver TranspI2000;6:686-702.) 
T he adaptive host-versus-graft: (HVG) immune re-
sponse to an allograft is analogous to the immune 
response to intracellular noncytopathic microorgan-
isms l -4 with more complex consequences because the 
mobile immunocompetent passenger leukocytes of an 
organ mount a contemporaneous graft-versus-host 
(GVH) reaction.4-7 We have proposed that the HVG 
and GVH reactions, each driven by the immunogenic 
cells of the opposing leukocyte population, are regu-
lated by the migration and localization of the respective 
leukocytes. 4 In this view, transplantation immunology 
is incomplete without accurate knowledge of the routes 
of migration, destination, and lineages of both popula-
tions of mobile leukocytes. 
The traffic of different lineages of donor cells from 
the graft to the lymphoid organs of the host and the 
heterogenous persistence of these cells (i.e., microchi-
merism) in nonlymphoid as well as lymphoid areas have 
been extensively documented in experimental studies of 
organ allograft acceptance and tolerance.s-12 Con-
versely, investigations ofleukocytes in the transplanted 
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organ have been concerned almost exclusively with the 
host-infiltrating lymphocytes and other host-effector 
leukocytes. 
The present study provides information about the 
proportions of donor and recipient leukocytes and their 
lineages in rat heart allografts transplanted to untreated 
or immunosuppressed naive recipients and nonimmu-
nosuppressed recipients that had been rendered par-
tially or completely tolerant by the previous transplan-
tation of donor-strain bone marrow cells (BMCs) or an 
orthotopic liver. Particular attention was focused on the 
leukocytes of myeloid precursor origin (i.e., nonlym-
phoid cells) that classically have been associated with 
rejection 13,14 and, more recently, with tolerance. 5-11 ,15 
The results allow a better understanding of the inter-
actions of the existing donor and recipient immuno-
cyte populations, how transplantation tolerance is ac-
quired, and especially the pathogenesis of chronic 
rejection (CR). 
Materials and Methods 
Animals and Surgical Procedures 
Male Brown Norway (BN, RTrn) and Lewis (LEW, RT11) 
rats, which differ at class I and II major histocompatibility 
complex (MHC) and mmor histocompatibility complex 
(mHC) loci, were purchased from Harlan Sprague Dawley 
Inc (Indianapolis, IN) and kept in a specific pathogen-free 
animal facility. Maintenance of the animals and performance 
of all experiments conformed to the guidelines of the Council 
of Animal Care at the University of Pittsburgh (Pittsburgh, 
PAl. HeartS from 200- to 250-g naive LEW donors were 
transplanted to the abdominal site of 250- to 300-g BN re-
cipients or isograft controls (group 1) to LEW recipients 
(Table 1). The methods ofibt~ BN orthotopiclivertrans-
plantation and LEW BMC preparation and infusion into BN 
recipients were as previously reported. 11 ,16 
Experimental Design 
Normal LEW heans, isografts (group 1), and allografts were 
studied under the conditions listed in Table l. Na'ive BN 
allograft recipients either were not treated after transplanta-
tion (group 2) or were immunosuppressed with tacrolimus 
(T AC; Fujisawa Pharmaceutical Co Ltd, Osaka, Japan) for 28 
days only (group 3) or for the 100 days' duration of the 
experiments (group 4). 
Other BN recipients were preconditioned 100 days in 
advance of the cardiac transplantations with an infusion of 
2.5 X 108 LEW BMCs (group 5) or with the orthotopic 
transplantation of a LEW liver (group 6), Beginning on the 
day of the priming BMCs or liver transplantations, the ani-
mals were treated with the same 28-day course ofTAC used 
Table 1. Experimental Groups and Controls 
Post-Heart TX 
Group Recipient Priming Immunosuppression Previously Reported Effects9•11 ,16 
O. Normal LEW heart None None Not applicable 
1. Isografr conrrol None None None 
(LEW->LEW) 
2. No treatment None None Acute irreversible rejection at 9 days 
3. ShortTAC None Short-course TAC CR associated with decline of 
days 0-28' microchimerism 
4. LongTAC None Continuous TAC Freedom from acute rejection and CR 
days O-IOOt associated with stable 
microchimerism 
5. BMC prime 2.5 X 108 LEW BMCs day -100; None Parcial drug-independent tolerance 
TAC days -100 to -87, and days but subtle CR less severe than in 
-80 and -73* group 3, associated with decline of 
chimerism 
6. Liver TX prime LEW orthotopic liver on day -100; None Complete drug-free tolerance 
same TAC therapy as group 5:j: associated with robust 
microchimerism 
NOTE. Heart transplantations were on day O. 
Abbreviation: TX, transplantation. 
* 1.0 mg/kg/d ofTAC days 0-13, 20, and 27. 
t 1.0 mg/kg/d ofTAC days 0-13 and once weekly thereafrer until animals were killed at 100 days. 
:j: 1.0 mg/kg/d ofTAC days -100 to -87 and additional doses on days -80 and -73. Animals were drug free for 73 days before test 
heart transplantation. 
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for the na'ive heart recipients of group 3. At the time of the 
challenge heart transplantations, these animals had been 
TAC-free for 73 days and had no trace ofTAC in their blood. 
Heart-cell suspensions. The percentage of leukocytes 
(CD45 + cells) relative to the number of cardiac myocyres and 
other nonleukocyte (CD45-) cells was determined by flow 
cytometry of cell suspensions prepared from normal and 
transplanted LEW heartS. The control CD45+ ICD4S- ratio 
(l:4 to 1:5 in normal LEW heartS and isografts [group 1]) was 
compared with the ratios in cell suspensions of allografts 
(groups 2 through 6) removed when the animals were killed 5 
and 100 days after transplantation under the experimental 
conditions listed in Table 1. The donor and recipient propor-
tions of the total CD4s+ population and of the myeloid 
subpopulations were directly determined. The CD4S+ leu-
kocytes not stained with the myeloid lineage-specific mono-
elonal antibody (mAb; Table 2) were assumed to be mostly 
lymphoid cells. 
Intact tissues. In separate experiments, tissue sections of 
the transplanted hearts and host spleens were studied with 
immunohistochemistry (IHC). For these studies, 3 to 6 ani-
mals in all 6 experimental groups were killed·l, 3, 5, and 9 to 
10 days after heart transplantation. In groups 1 and 3 through 
6, in which all hearts continued to beat for the variable periods 
of observation before the animals were killed, recipients also 
were killed at 15, 30, and 100 days. Portions of the heart grafts 
and recipient spleens (and in group 6, of the priming liver 
allografts) were fixed in formalin for routine histopathologic 
examination, placed in optimal cold temperature (OCT) 
compound, and snap-frozen for messenger RNA (mRNA) 
extraction. 
Cell Isolation From Heart Grafts 
At the time the animals were killed, the heartS were perfused 
in situ through the aorta with 20 mL of Hank's balanced salt 
solution followed by 20 mL ofRPMI-1640 containing 0.05% 
collagenase (Type B; Boehringer Mannheim, Mannheim, 
Germany), 0.003% DNase (type IV; Sigma, Sr Louis, MO), 
10 mmoliL of N-2-hydroxyethylpiperazine-propanesulfonic 
acid (HEPES), 1 mmol/L of L-glutamine, 50 J-Lg/mL of gen-
tamicin, and 5% fetal bovine serum (all from Life Technolo-
gies, Grand Island, NY). 
The bloodless hearts were cut into small pieces, digested in 
a water bath for 60 minutes at 37°C, and then passed through 
nylon mesh. Isolated cells were washed twice with RPMI-
1640 and further purified by centrifugation over Ficoll-Paque 
(specific gravity, 1.077; Biotech AB, Uppsala, Sweden). 
Flow Cytometry 
After the Ficoll-Paque centrifugation, the heart-cell suspen-
sions were analyzed with 3-color flow cytometry, using the 
mAbs listed in Table 2. Normal splenocyres were used in each 
experiment to confirm the accuracy of staining of the mAbs. 
Total leukocytes. Phycoerythrin-conjugated OXI (CD45) 
was used to distinguish hematolymphopoietic cells from pa-
renchymal cells. 
Donor and recipient phenotypes. This distinction was made 
with affiniry-purified biotinylated mAb 163 and mAb 42, 
which are specific for the RTl.AI antigen (LEW MHC class 
I) and the RTl.An antigen (BN MHC class I), respectively,l7 
Cy-chrome-conjugated streptavidin (PharMingen, San Di-
ego, CA) was used as a secondary antibody. In addition, donor 
MHC class n+ cells were identified by mAb L21-6, which is 
Table 2. Panel of Monoclonal Antibodies Used in This Study I 
Clone Specificity Isotype Concentration Supplier 
Lineages 
OXI C045, leukocyte common antigen Mouse IgGl, K 1:200 PharMingen* 
OX42 CO II bl c, myeloid cells Mouse IgG2a, K 1:100 PharMingen 
EDl C068, monocy(es/infilrrarive macrophages Mouse IgGI 1:100 Serored 
E02 Tissue macro phages Mouse IgGl 1:100 Sero(ec 
Cosrimulawry molecules 
3H5 C080, B7-1 Mouse IgGl, K 1:100 PharMingen 
24F C086, B7-2 Mouse IgGI, K 1:100 PharMingen 
MHC antigens 
163 Class I MHC on LEW (RTl.AI) Rat IgG2b 1:400 Dr H.W. Kunz:f: 
42 Class [ MHC on BN (RTI.A") Rat IgG2a 1:500 Dr H.W. Kunz 
L21-6 Class II MHC on LEW Mouse IgGl 1: 1.200 Dr y, Iwakij: 
AbbreVIation: IgG. immunoglobulin G . 
• San Diego, C\. 
t Kidlingwn, Oxford. UK. 
+ University of Pittsburgh, Pittsburgh, PA. 
--
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specific for MHC class II antigens on LEW, but not BN, 
cells. IS 
Nonlymphoid leukocytes. The subset of CD45 + leukocytes 
expressing CD 11 h/e (myeloid precursor-derived cells) was 
delineated by staining with OX42 antibody. OX42 is a 
marker for leukocyte integrin Mac-l (CDllb, CDI8) and 
p150.95 (CDllc, CDI8) on macro phages, monocytes, den-
dritic cells (DCs), and granulocytes. 
Macrophages. ED 1 mAb was used to identify cells of the 
mononuclear/phagocyte system. 19,20 Tissue macro phages 
were identified with mAb ED2,19,21 the specificiry of which is 
similar to mAb BMAC-5,22 
IRC 
Frozen samples in OCT compound were sectioned at 4 J.Lm 
and stained with a routine indirect avidin-biotin complex 
method, as previously described,23 Sequential changes in the 
numbers and location of class II+ donor cells were deter-
mined with the L21-6 mAb,IB The number of positively 
stained cells was determined by blindly counting the number 
oflabeled cells in 20 high-power fields (HPFs)/section (orig-
inal magnification X400). When the section contained more 
than 5 L21-6+ cells/HPF, double labeling was performed 
with other mAbs that included 3H5 (B7-1, CDSO), 24F 
(B7-2, CDS6), EDl, and ED2 (Table 2). Isotype-matched 
nonimmune antibody was used for negative control for each 
assay, 
Programmed Cell Death 
Apoptosis, After formalin-fixed sections were deparaf-
finized, the slides were treated with proteinase K (40 mg/ mL; 
Sigma) for 15 minutes at 37°C. Apoptosis was quantitated 
with the terminal deoxynucleotidyl transferase-mediated bi-
otin deoxyuridine triphosphase nick end labeling (TUNEL) 
method using Apop Tag kit (Intergen, Purchase, NY). Posi-
tively stained cells were counted according to the procedure 
used in IHC (previously discussed). 
Caspase-3-like activity, A frozen portion of the heart allo-
graft was used to determine caspase-3-like activity. A portion 
of the heart allograft was homogenized in 10 mrnollL 
of HEPES (pH 7.4) comaining the protease inhibitors 
(0.5 mmollL of phenylmethylsufonyl fluoride, 5 f.Lg/mL of 
aprotinin, 5 J.Lg/mL of peps tat in, and 10 f.Lg/mL of leu pep-
tin), Crude cytosol was obtained after cemrifugation at 
12,000gfor 20 minutes at 4°C. The enzyme reaction mixture 
contained 200 J.Lg of cytosolic protein and 200 f.LmollL of 
AC-DEVD-pNA in 150 f.LL of reaction buffer (100 mmol/L 
of HE PES, 20% glycerol, 5 mmol/L of dithiothreitol [DTT] 
and protease inhibitors). The enzyme reaction was initiated 
by adding the substrate to a 96-well plate containing the 
enzyme solution at 3rc. The caspase-3-like activiry was 
calculated from the initial velocity by measuring the increased 
absorbency at 405 nm every 15 minutes. The reaction mix-
ture without enzyme or substrate was used as a control. 
----------------------------
Ribonuclease Protection Assay of Cytokines 
Total RNA was extracted from frozen samples by llsing 
TRlZOL Reagent (Life Technologies) according ro the man-
ufacturer's instructions. The concentration of RNA was de-
termined by UV spectrophotometer at 260 nm. The ribonu-
clease (RNase) protection assay (RPA) was performed by 
using commercially available kits and following the manufac-
turer's instructions (all from PharMingen). 
Radiolabeled antisense RNA multiple probes were synthe-
sized using an in vitro transcription kit and rat cytokine mul-
tiprobe template set (rCK-l), which included probes for cy-
tokines (interieukin-lO' [IL-la], IL-lj3, IL-2, IL-3, IL-4, 
IL-5, IL-6, IL-l 0, tumor necrosis factor-a [TNF-a], TNF-f3, 
and interferon-y) and housekeeping genes (L32 and 
GAPDH). 32P-labeled probes (8.0 X 105 cpm) and sample 
RNA (5 J.Lg) were hybridized at 56°C for 12 to 16 hours, and 
single-stranded RNAs including antisense RNA probes were 
digested. The protected RNA duplexes were isolated by 
RNase inactivation/precipitation solution (Ambion Inc, Aus-
tin, TX) and electrophoresed in a standard sequencing gel. 
Dried gels were exposed to Storage Phosphor Screen (Molec-
ular Dynamics, Sunnyvale, CA) for 12 hours at room temper-
ature, and the radioactivity of each band was measured by 
j3-scan (PhosphorImager; Molecular Dynamics) and NIH 
Image (download from http://rsb.info.nih.gov/nih-imagel). 
The results were normalized to GAPDH and expressed as 
ratios of cytokine-GAPDH. 
Mixed Lymphocyte Reactions 
In vitro antidonor reactivity of the primed BN recipients was 
assayed with I-way mixed leukocyte reactions. Responder 
cervical lymph node lymphocytes were obtained just before 
challenge heart transplantation from the BN rats primed 100 
days previously with LEW BMCs (group 5) or LEW liver 
grafts (group 6) and from naIve BN rats (control). Lymph 
node lymphocytes from naive BN (recipient strain), LEW 
(donor strain), and ACI (third-party) rats were used as stim-
ulator cells, Technical details have been reported. I I After de-
termining thymidine uptake with a liquid scintillation 
counter (Wallace Inc, Gaithersberg, MD), the stimulation 
index (SI) was calculated as follows: 
SI = cpm (experimental animal 
X stimulator [AJ)/cpm (experimental animal 
X stimulator [normal BN]) 
Statistical Analysis 
Results of flow cytometry, IHC, and RPA are presented as 
mean::: SD. Data were analyzed by l-way analysis of variance 
(ANOVA), Fisher's PLSD test, and Student's t-test. Statisti-
cal significance is established at P less than .05. 
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Results 
Graft Outcome 
Naive nontreated recipients. Although the LEW iso-
grafts (group 1) had indefinite survival, the LEW car-
diac allografts (group 2) were irreversibly rejected with 
cessation of hearrbeat after 9.6 ::!: 1.3 days (n = 7). 
Immunosuppressed or primed recipients. None of the al-
lografts in groups 3 through 6 was lost to rejection. At 
the time the animals were killed, there were no discern-
ible differences between groups in the gross appearance 
or estimated strength of heartbeat. CR was undetect-
able by histopathologic examination of the transplanted 
hearts of continuous-TAC-treatment group 4 and liver-
primed group 6 (Table 1). 
With microscopic examination of tissue sections, 
the presence of CR in the hearts of short-course-TAC 
group 3 and BMC-primed group 5 was obvious with 
evaluations recorded9•Jl .16 without knowledge of the 
experimental groups. The findings of CR included 
obliterative arteriopathy and multiple perivascular and 
subendocardial lymphocytic infiltrates similar to the 
"Quilty" lesions seen in human cardiac allografts. 16 
They were the most advanced in the cardiac allografts of 
shorr-course-TAC group 3. 
Flow Cytometry of Heart-Cell Suspensions 
CD45+ cells. Between one fourth and one fifth of the 
nucleated cells in suspensions prepared from normal 
LEW hearts or 5-day LEW isografts stained with the 
pan leukocyte OXI mAb (Table 3). The leukocyte frac-
tion increased 4-fold by 5 days (to >80%) in allografts 
transplanted to untreated (group 2) or BMC-primed 
BN recipients (group 5), and it doubled when the trans-
plantations were to TAC-treated (groups 3 and 4) or 
liver-primed recipients (group 6; Table 3). 
After 100 days, 47% of the cells in the heart allo-
grafts ofBMC-primed group 5 still were CD45+, and 
in the short-course-T AC group 3, the leukocytes ac-
counted for 82% of cells. By this time, the leukocyte-
nonleukocyte (CD4 5 + -CD45-) ratio in the CR-free 
allografts of the continuous-T AC group 4 and the drug-
free but liver-primed group 6 had returned to the range 
of normal hearts. 
Donor-recipient phenotypes. Five days after transplanta-
tion, only 2.5% to 3% of the CD45+ cells remaim:d 
LEW (i.e., costained with mAb 163) in the heart allo-
grafts of the untreated naive recipients (group 2) and 
the heart allografts of recipients primed with LEW 
BMCs (group 5; Table 4). In contrast, 28.6% of the 
CD45+ cells remained LEW in the 5-day hearts trans-
planted to TAC-treated naIve recipients (groups 3 and 
4), and 22% were still LEW in the cardiac allografts of 
liver-primed recipients (group 6). 
At 100 days, LEW (donor) cells accounted for 1 % to 
2% of the CD45 + population in the heart allografts of 
groups 3 (shorr-course TAC) and 5 (BMC primed) 
compared with 30.5% in the continuous-TAC group 4 
and 8.4% in the liver-primed group 6 (Table 4). 
CD 11 ble + cells. Leukocytes coexpressing CD 11 bl c 
made up approximately half the CD45 + leukocytes of 
normal LEW hearts and LEW isografts throughout the 
100 days of the experiment (Table 5). In allografts, the 
CD 11 bl c + fraction was sustained only in naive re-
cipients treated continuously with TAC (group 4; Fig. 
1). In the BMC- and liver-primed groups 5 and 6, this 
fraction was already reduced by 5 days, and in the 
Table 3. Leukocyte (CD45+ Cell) Percentage of Contribution to Total Nucleated Cells in Suspensions Prepared From LEW Hearts 
5 and 100 Days After Isotransplantation or Allotransplantation 
Day 5: Day 100: 
Group No. %CD45+ Cells No. %CD45+ Cells 
O. Normal heart 8 19.9 = 2.5 8 19.9 = 2.5 
I. Isograft control 6 25.0 = 5.8 3 13.0 = 0.7 
2. No treatment 5 81.8 = 8.7' NA NA 
3. ShorrTAC 5 45.4 = 9.0' 3 81.9 ::: 5.4' 
4. LongTAC 5 45.4::: 9.0' 3 14.7 :c:: 4.0 
5. BMC prime 6 86.4 ::: 10.7* 3 47.3 ::: 4.7' 
G. Liver TX prime 5 52.6=7.1' 3 20.8 = 1.4 
NOTE. Normal hean data from naive animals that did not undergo transplantation. 
Abbreviation: NA. not applicable. 
« p < .0001 compared wich che normal heart and isografcs. 
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Table 4. Percentage Contribution of LEW and BN Cells to the Leukocyre (CD4S+) Population in the Cell Suspensions Shown in 
Table 3 5 and 100 Days After Isotransplantation or Allotransplantation 
Day 5 % of CD4 S - Cells Dav 100 % ofCD45- CeJJs 
LEW Class I LEW Class I 
Group No. (LEW Class Il) BN Class I No. (LEW Class II) BN Class I 
O. ~ ormal heart 8 98.7:!: 1.17 (24.9 :!: 4.7) NT 8 98.7:!: 1.17 (24.9 :!: 4.7) NT 
1. Isograft con trol 6 98.6:!: 0.7 (28.7 :!: 4.4) 0.6 :!: 0.3 3 99.2 :!: 0.4 (29.2 :!: 0.2) 0.8 :!: 0.2 
2. No treatment 5 3.0 :!: 0.9 (1.8 :!: 0.5) 97.4 :!: 1.0 NA NA NA 
3. ShortTAC 5 28.6 :!: 6.1 (3.3 :!: 0.2) 69.4:!: 2.6 3 2.0 :!: 0.8 « 1.0) 98.2:!: 0.9 
4. LongTAC 5 28.6 :!: 6.1 (3.3 :!: 0.2) 69.4 :!: 2.6 3 30.5 :!: 7.4 (4.3 :!: 1.6) 69.0:!: 9.0 
5. BMC prime 6 2.s:!: 1.1 0.7 :!: 0.4) 97.8 :!: 0.9 3 1.2 :!: 07 «1.0) 98.2:!: 1.0 
6. Liver TX prime 5 22.0:!: 7.6 (9.2 :!: 3.9) 79.3 :!: 8.7 3 8.4 :!: 2.4 (2.0 :!: 0.5) 92.0:!: 2.8 
NOTE. DC-rich subset ofL21-6+ LEW ceJJs is in parentheses. Normal heart data from naive animals that did not undergo transplan. 
tation. 
Abbreviations: TX, transplantation; NA. not applicable; NT. not tested. 
short-course-T AC group 3, the depletion occurred after 
discontinuance of treatment (Fig. 1; Table 5). By infer-
ence, the 67% to 69% of leukocytes that were 
CDllb/c- in the 100-day allografts of drug-free recip-
ients groups 3, 5, and 6 consisted of lymphoid cells 
compared with approximately 50% in IOO-day 
isografts (group 1) and the TAC-protected allografts of 
group 4 (Fig. 1). 
The CD 11 bl c + cells included donor (LEW) as well 
as recipient (BN) leukocytes in all groups of allografts at 
both time points (Table 5). However, the hearts in the 
continuous-TAC group 4 differed from all other 100-
day allografts in that fully half of their CD 11 bl c + cells 
were donor, a representation of donor cells many times 
greater than in any other experimental group (Table 5). 
EDl+ IED2+ cells. Approximately 30% of the 
CD45+ cells in the cell suspensions of normal LEW 
hearts and isografts stained with the ED2 mAb, which 
has been reported to identifY tissue macrophages19•21 
(Fig. 2). Except in animals under continuous treatment 
with TAC (group 4), a remarkable reduction in ED2+ 
cells was seen over the course of 100 days in all groups of 
allografts. By day 100. the majority of the reduced 
numbers ofED2 + cells in the hearts of groups 3, 5, and 
6 were recipient phenotype. Conversely, the fraction of 
ED2 + cells in the continuous-T AC heart allografts 
(group 4) was fully maintained; the majority was made 
up by LEW (donor) cells (Fig. 2). 
In normal LEW hearts, the monocytes/phagocytes 
identified with EDl mAb were only 1115 as numerous 
as the ED2+ cells. Contrary to the reduced ED2+ cell 
population in most of the allograft groups, the ED1 
macrophage fraction was increased in all groups from 
the very small percentage (::::;2%) found in normal 
hearts. The increases at 5 days were most dramatic (to 
7.6%) in the untreated group 2 hearts. The vast major-
ity of these cells were BN (Fig. 2). 
At 100 days, when the histopathologic determina-
tions ofCR were made, the ED I fraction was greatest in 
the CR-affiicted allografts of the short-course-T AC 
group 3 and the heart allografts of the BMC-primed 
group 5 (both 5%). Smaller increases (to 3.5%) were 
seen in the CR-free allografts of the continuous-T AC 
group 4 and the liver-primed group 6 (Fig. 2). Similar 
to the findings at S days, most of the ED 1 cells were BN 
(recipient). 
The L21-o+" population. These LEW-specific MHC 
class n+ cells, which have many characteristics of 
DCS,8.ll made up 24.9% of the total CD4S+ leuko-
cytes of normal hearts (Table 4). Less than two thirds of 
the L21-6+ cells (a fraction of 0.59) coexpressed 
CDIlb/c (light shade, Fig. 3). By inference, the re-
maining fraction ofL21-6+ leukocytes in normal hearts 
(-41 %) consisted of lymphoid cells (dark shade. 
Fig. 3). 
The CDllb/c+ fraction of the L21-6+ population 
in the 5-day and 100-day allografts was not different 
from that in the isografts, except in the 1 DO-day heartS 
of recipients treated with continuous TAC (group 4). 
In the exceptional group 4. the myeloid fraction of the 
L21-6+ cells in the IOO-day allografts was only 0.33 
(Fig. 3), leaving 0.67 of presumed L21-6+ lymphoid 
cells. 
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Figure 1. Fraction of CD45 + cells (leukocytes) that were 
CDllb/c+ (myeloid precursor-derived) in the cell sus-
pensions of control (group 0) and transplanted LEW 
isografts (group 1) and allografts (groups 2 through 6) 
after 5 and 100 days' residence in the host. Note the low 
CDllb/c representation at day 5 in the BMC-primed 
group 5 and the liver-primed group 6. At day 100, the 
CD 11 bl c traction remained low in these groups, and it 
had been reduced in group 3 after discontinuance ofTAC. 
IHe 
LEW MHC class Ir EiO1-~F leukocytes. Throughout 
the normal LEW heart, strong staining was seen on 
homogeneously distributed spindled interstitial cells 
that had the morphological characteristics of DCs. 
These cells rapidly disappeared from the rejecting LEW 
cardiac allografts transplanted to untreated BN rats 
(group 2) while appearing III the recipient spleens 
(Fig.4A). 
Similarly, L21-6+ cells were promptly reduced in 
the LEW heart allografts of naive BN recipients treated 
continuously with TAC (group 4), but small numbers 
were detectable at 30 days and after 100 days (Fig. 4B). 
L21-6 -'- cells were not seen in the spleens of these T AC-
treated recipients until 30 days posttransplantation, 
and then only in small numbers (Fig. 4B). It could not 
be determined whether the paucity ofL21-6+ cells in 
the spleen at both 30 and IDa days in group 4 was 
caused by the absence of these cells or by downregula-
tion of MHC class II antigens, as described with de-
oxyspergualin.24 
L21-6+ cells also declined rapidly in the heart allo-
grafts of the drug-free BMC-primed recipients of group 
5, but they were rarely seen in the spleen (Fig. 4C). 
Between 30 and 100 days, they remained sparse in both 
locations. 
Conversely, the L21-6+ cells in the heart allografts 
of the liver-primed recipients (group 6) were at least as 
numerous as in normal LEW hearts throughout the 
entire lOa days after cardiac transplantation (Fig. 40). 
They also transiently increased lD the host spleen, 
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Figure 2. Flow cytometric analysis of heart-cell suspensions obtained from different experimental groups 5 and 100 days 
after transplantation (Tx). Subsets of ED 1 + and ED2+ macrophages are shown with a breakdown of LEW (donor) and 
BN (recipient) constituencies. All data are expressed as percentages of CD45 + cells. 
peaked there at 15 days, and returned to baseline levels 
by 30 days. The donor specificity of the L21-6 mAb was 
shown by the total absence of staining in naIve BN 
spleens. These findings in the liver-primed group 6 and 
also those in group 5 confirmed previous reported ob-
servations. 16 
In addition to the heart studies, the L21-6 + cell 
population of the priming LEW livers was determined 
before hepatic transplantation, during the 1 DO-day res-
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0.8 
0.6 
0.4 
0.2 
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Figure 3. The myeloid (i.e., CDllb/c+) fraction (light 
shading) of LEW-specific MHC class n+ (L21-6+) leuko-
cytes in cell suspensions prepared from normal LEW 
hearts (group 0) and LEW isografrs (group I) and allo-
grafts (groups 2 through 6) 5 and 100 days after transplan-
tation. Note that 59% to 85% of the L21-6+ cells are 
myeloid derived except in the 100-day hearts of recipients 
under active TAC therapy, in which the L21-6+ 
CDIIb/c + cells are a distinct minority (33%). 
idence of the priming liver before challenge heart trans-
plantation (data not shown), and for 100 days after the 
heart transplantations. After transplantation of the 
challenge LEW hearts, the number ofL21-6+ cells in 
the priming liver allografts was changed very little by 
the challenge heart transplantation at the time or for the 
next 100 days' residence of the cardiac grafts (Fig. 4D). 
The normal nontransplanted LEW liver expressed 
only 6.5 :±: 3.6 L21-6+ cells/HPF, most with the mor-
phological features of DCs. Thus, the expression of 20 
to 30 of these class 11+ cells/HPF in the liver allograft at 
the time of challenge heart transplantation and for the 
subsequent 100 days was 3 to 5 times greater than 
normal. The cells had the typical appearance and loca-
tion ofDCs (portal triad) and Kupffer cells (sinusoids). 
Costimulatory molecule expression. CDSO (B7-l) was 
not detected with single-color IHC staining in trans-
planted cardiac isografts or allografts (or in the host 
spleens) of any of the animals of groups 1 through 6 
(data not shown). The validity of this observation was 
supported by strong CDSO expression in the spleens of 
lipopolysaccharide-injected na'ive BN rats (positive 
control). The staining was of large and irregularly 
shaped cells located in the splenic periarteriolar lym-
phoid sheaths and small round cells in the splenic ger-
minal centers (presumably DCs and macrophages). 
In contrast to the negative CD80 observations, in-
terstitial dendritic-shaped cells in normal LEW hearts 
were CD86+ (B7-2) at a frequency of 0.50 :±: 0.67/ 
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Figure 4. Sequential changes of L21-6+ cells in tissue 
sections of LEW heart allografts and BN recipient spleens 
after transplantation into (A) naive animals without im-
munosuppression (group 2), (B) under coutinuous-TAC 
(group 4), (C) BMC-primed (group 5), and (D) liver 
transplant (Tx)-primed (group 6) recipients. For group 6, 
data are included from the LEW liver allografts that had 
been used for priming and been in place for 100 days by 
the time of challenge heart transplantation. After immu-
nohistochemical staining, the number ofL21-6+ cells was 
determined in 20 HPFs at original magnification x400. 
Data from 3 to 6 animals at each time point are expressed 
as mean ± SD. (POD, postoperative day.) 
HPF, a rate similar to that in LEW cardiac isografts 
from 1 to 100 days after their transplantation (group 1; 
Fig. 5, left). In contrast, CD86+ cells increased 5- to 
10-fold by days 5 through lOin the LEW heart allo-
grafts of naive, untreated BN recipients (group 2) and 
na'ive recipients immunosuppressed with T AC (group 
4). The CD86+ cells were found in aggregates located 
mainly in the interstitium, perivascular area, and epi-
cardium, suggesting that they were infiltrating recipient 
leukocytes. Of interest, no difference in the number, 
location, and appearance of these cells could be distin-
guished to 10 days in the transplanted hearts of un-
treated group 2 and the continuous-TAC group 4; 
however, the CD86+ cells subsequently declined in 
group 4. These analyses were not performed in the 
short-course-TAC group 3. 
CD86 expression was most frequently observed in 
the LEW heart allografts transplanted to the BMC-
primed BN recipients of group 5 (Fig. 5, right). The 
CD86+ cells appeared 3 days after challenge heart 
transplantation, reached a zenith of 6 ::!: 2.1/HPF after 
5 days (a 10- to 20-fold increase), and returned to 
normal levels by 100 days. With blind reading of the 
slides, the findings in the BMC-primed group 5 at day 
5 could not be distinguished from those in the allografts 
of group 2 (no treatment) or group 4 (T AC treatment). 
The heart allografts transplanted to liver-primed BN 
recipients were unique in that CD86+ cells were found 
only slightly more frequently throughout the 100 days 
posttransplantation than in LEW isografts and normal 
LEW hearts (Fig. 5, right). 
Identification of donor CaU~ cells. Double immuno-
staining with anti-CD86 mAb 24F and donor-specific 
L21-6 was performed on heart allografts obtained on 
posttransplantation day 5, the time of highest CD86+ 
cell yield. In groups 2 through 5, the focally aggregated 
CD86+ cells at day 5 were L21-6-, confirming the 
Naive reCipients -0- O. Normal heart 
-Ir- 1. Isograft 
Primed recipients __ 5. BMC·primed Figure 5. Sequential deter-
mination in tissue sections of 
CD86 (B7-2) expression in 
different types of heart allo-
grafts. After immunohisto-
chemical staining, the num-
ber of CD86+ cells was 
determined in 20 HPFs at 
original magnification x 400. 
Data from 3 to 6 animals at 
each time point are expressed 
as mean ± SD. * P < .05 ver-
sus normal heart (I-way 
ANOVA). 
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impression from single CD86 staining that these were 
infiltrating recipient cells rather than donor leukocytes. 
The findings at day 5 in the heart allografts trans-
planted to liver-primed recipients were of special inter-
est and also in agreement with the single-staining results 
with L21-6 or rnAb 24F (CD86). Almost no L21-6-
(recipient) cells were found to express CD86. The ma-
jority of the abundant L21-6+ (donor) cells also were 
CD86-, but some coexpressed CD86 (Fig. 6). The ob-
servation that donor rather than recipient class n+ DC-
like cells in the transplanted hearts of these pretolerized 
animals coexpressed CD86 (B7-2) was consistent with 
our previous demonstration that naIve passenger leuko-
cytes from an allograft transplanted to a pretolerized 
(i.e., now defenseless) recipient could mount an unop-
posed GVH reaction similar to that in parent-to-off-
spring FJ hybrid models.9 
Apoptosis 
Normal LEW hearts had 0.4 ::!: 0.1 TUNEL-positive 
cells/HPF. This count increased dramatically to apeak 
at 5 days in the cardiac allografts of untreated naIve BN 
recipients (group 2) in association with increases in 
caspase-3-like activity and then receded as the hearts 
rejected (Fig. 7, left). An increase in TUNEL-positive 
cells was low grade by comparison and delayed in the 
T AC-treated naIve recipient group 4, and there was 
little or no parallel change in caspase-3-like activity 
(Fig. 7, left). 
The TUNEL + cell count in LEW hearts of the 
.-. ," 
.. , 
BMC- and liver-primed groups 5 and 6 increased sev-
eral fold during the first 2 weeks after transplantation 
and remained elevated throughout the 100 days of ob-
servation (Fig. 7, right). Compared with the values in 
normal hearts, the increases were significant at 10 and 
15 days in group 5, but not in group 6. Elevations in 
caspase-3-like activity greater than that of normal heart 
controls were recorded at posttransplantation days 3, 5, 
and 100 in 8 of the 10 hearts removed from the BM C-
primed group, but not 8 hearts retrieved from liver-
primed recipients (Fig. 7, right). 
Cytokine Profiles 
The elevations in mRNA of 6 representative cytokines 
in the LEW allograft of groups 2 through 6 are shown 
for the first 5 posttransplantation days in Figure 8. The 
seemingly large increases in mRNA ofIL-l {3 were illu-
sory because of the exquisite sensitivity of the assay. The 
increases in the untreated group 2 were blunted but not 
prevented by treatment with TAC (groups 3 and 4). 
Interestingly, the increases in mRNA of cytokines 
in allografts transplanted to BMC-primed recipients 
(group 5) were just as prompt and as great or greater 
than those in the hearts transplanted to the untreated 
naIve recipients of group 2, with the exception ofIL-2. 
However, the increases in group 5 were quickly revers-
ible. In comparison, the cytokine profile was relatively 
little affected in the liver-primed recipients by challenge 
heart transplantation. 
'.B , '," ''ill> .;" .' 
\ 
\ 
Figure 6. Double immunohistochemical stain of LEW MHC class II and CD86 with L21-6 mAb (3-amino-9-ethylcar-
bazole; red) and 24F mAb (blue alkaline phosphatase substrate kit N; blue) in heart allografts 5 days after transplanta-
tion. (A) Untreated naive BN recipient of group 2. Note many CD86+ cdls associated with disappearance ofL21-6+ cells 
and the upregulation ofMHC class II on the microvasculature. (B) Heart allograft of group 6 in liver-primed recipient. 
Note double-positive purple donor cells (L21-6+, CD86+; arrow) among many single-stained L21-6+ cells but almost no 
single-stained CD86+ cells in the interstitium of the heart graft, i.e., a few MHC class n+ donor cells with upregulated 
B7 -2 but essentially no recipient cells because the recipient was pretolerized to the donor. (Original magnification x 200.) 
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Figure 7. Apoptosis determined by TUNEL assay and caspase-3-like activity in different types of heart allografts. The 
number ofTUNEL-positive cells in heart allograft sections was determined in 20 HPFs at original magnification x400. 
Data from 3 to 5 animals at each time point are expressed as mean ± SD. In caspase-3-like activity, each dot represents 
the result from an individual animal.*P < .05 versus normal heart (I-way ANOYA). 
Mixed Leukocyte Reaction 
Donor-specific immune reactivity just before challenge 
transplantation with LEW hearts (Fig. 9) was most 
depressed in the liver-primed BN recipients (group 5; 
p < .01), and less so in BMC-primed recipients (group 
4; P = not significant). The response to ACI (third-
party) stimulatory cells was normal. 
Discussion 
Evidence has accumulated consistent with the para-
digm that organ engraftment results from an acute dou-
ble immune reaction in which donor and recipient leu-
kocytes induce reciprocal clonal expansion followed by 
peripheral clonal deletion,4.7,25 the maintenance of 
which requires the persistence of donor leukocytes. l I.26 
We have further proposed that the migration and local-
ization of the leukoCYtes regulates the HVG and GVH 
responses," exemplifYing an immune governance prin-
ciple that applies to all antigens.4 ,27.29 In essence, HVG 
and GVH cytotoxic T-cell responses either are not in-
duced (immune indifference) or cannot be maintained4 
unless the respective donor and recipient alia antigens 
reach organized lymphoid collections that are epito-
mized by, but not limited to, the lymphoid organs. 
It could be postulated that recipient Des or other 
antigen-presenting leukocytes can endocytose apopto-
tic and! or necrotic donor cells and transport the peptide 
residue to lymphoid organs,30.33 theoretically orches-
trating T-cell immunity, including the preservation of 
self.34 We have argued instead that the only mobile 
donor antigen capable of reaching host lymphoid 0[-
gans and inducing enough of an HVG response to cause 
clonal exhaustion-deletion is the donor passenger leu-
kocyte population. The donor leukocytes migrate pref-
erentially to the recipient lymphoid organs, '),35,36 where 
they may induce and exhaust antigraft T cells. Recipro-
cally, activated antihost donor T cells among the pas-
senger leukocytes either cause GVH disease or are de-
leted.4 
This concept mandates evaluation of numerous pre-
viously unchallenged dogmas of transplantation immu-
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Figure 8. Cytokine mRNA levels in heart grafts deter-
mined by RPA. (IFN, interferon.) 
nology. For example, it has long been assumed that 
passenger leukocytes of an allograft are highly immuno-
genic, whereas parenchymal cells are nor. The leukocyte 
immunogenicity has been widely attributed to their 
expression of MHC class II andlor costimulatory (e.g., 
B7) molecules. Contraty to chis assumption, the pas-
senger leukocytes in the antigen migration-localization 
paradigm only appear to be immunogenic because of 
their ability to migrate to lymphoid organs, whereas the 
so-called nonimmunogenicity of organ parenchymal 
cells is caused by their immobilization within the organ 
architecture. This would readily explain the otherwise 
enigmatic observation by Bumgardner et al37-39 that 
when hepatocytes are isolated and infused, they are as 
immunogenic, if not more so, than hepatic passenger 
leukocytes. 
It also is apparent that experiments in which donor 
leukocytes are subtracted from an organ (epitomized 
by the use of "parking" models) are inappropriate for 
studies of tolerance mechanisms because the essential 
tolerogenic step of immune activation is eliminated at 
the outset. Moreover, the studies reported here show 
that the donor-strain leukocytes in allografts parked 
in ostensibly tolerant recipients are not uniformly re-
placed, as commonly believed. Finally, the absence of 
CR in organ allografts during the parking or after re-
transplantation cannot be assumed without examining 
the allograft histopathologically and without analysis of 
its leukocyte composition. 
Although the host lymphoid organs undoubtedly 
have the crucial role in the double-immune reaction of 
transplant rejection, the observations reported here are 
consistent with the possibility that immune responses 
also may be induced locally in the organ allografts, 
which quickly develop the immunogenic-tolerogenic 
characteristics of an ectopic organized lymphoid collec-
tion. Evidence of an intragraft GVH reaction mounted 
by the graft's passenger leukocytes has been reported in 
animals40 and humans.41 Consistent with such reports, 
B7 was expressed by donor but almost no recipient cells 
in the LEW heart allografts of the present study that 
had been transplanted to BN recipients who were im-
munologically defenseless because they had been pre-
tolerized with an orthotopic LEW liver (group 6). The 
other way around, we23 and others42 have described 
antigraft host T cells assembled in rosettes around do-
nor DCs in rejecting rat organ allografts, suggesting the 
local induction of an HVG response. 
By 5 days, the cardiac allografts in all our experimen-
tal groups had become major repositories of donor and 
recipient leukocytes, replete with cytokines and growth 
factors and with cell-to-cell proximity of multiple leu-
<.01 
)( 
0> 
't> 
E 
c: 
0 LEW 
0 
~ • ACI ::; 
E $ 
Figure 9. Mixed lymphocyte reactions of cervical lymph 
node lymphocytes from normal BN rats and BN rats 
primed 100 days previously with BMCs or a liver allograft 
under a short course of TAC. Mean ± SD of 4 to 6 
animals. 
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kocyte lineages, even in the highly pretolerized recipi-
ents (liver-primed group 6) and the less efficiently pre-
tolerized recipients of group 5 that had been primed 
with donor BMCs. Sakamoto et al43 have shown that 
the allograft, with parenchymal cells that are syngeneic 
to the donor passenger leukocytes, provides the optimal 
mictoenvironment for donor leukocytes, including the 
precursor and stem cells that presumably are responsi-
ble for the multilineage nature of microchimerism, as 
well as macrochimerism.9 ,lo Thus, the organ allograft 
may be a critical site from which donor leukocytes are 
renewed and exported to destinations in the host.43 
By 100 days, the ratio ofleukocytes to nonleukocyte 
cells had returned to normal (1:4 to 1: 5) in the CR-free 
heart grafts of the continuous-T AC and the liver-
primed recipients (groups 4 and 6). However, the ratio 
remained elevated to 1: 1 in the hearts of the BM C-
primed group 5 that had moderate CR and to 5: 1 in the 
severely CR-afflicted heartS of the short-course-TAC 
group 3. Despite the finding in the hearts of group 3 
that leukocytes were 5 times more frNuent than all 
other nucleated cells combined, these 100-day hearts 
had a strong heartbeat and appeared normal. 
At both 5 and 100 days, the allograft leukocytes in all 
experimental groups included donor as well as recipient 
phenotypes. The greatest proportions of donor leuko-
cytes at both times were in the CR-free heart allografts 
that had the smallest (most normal) total leukocyte 
fraction, i.e., those of the continuous-TAC and liver-
primed groups 4 and 6. In the group 6 recipients, the 
Bow cytometry analyses of the total donor leukocyte 
fraction and class n+ donor subset identified with 
the L21-6 mAb were generally consistent with im-
munohistochemical studies of tissue sections. In 
both the heart allografts and priming liver allografts 
of group 6 recipients, robust levels of donor class n+ 
leukocytes within organ allografts paralleled but 
tended to exceed the donor leukocyte chimerism in 
recipient tissues, as we reported previously.9 In anal-
ogous clinical observations, O'Connell et al44 re-
ported that a large number of donor leukocytes in 
bronchoalveolar lavage specimens from human lung 
recipients was associated with the absence in the 
allograft of bronchiolitis obliterans, the hallmark le-
sion of CR in pulmonary allografts. 4s 
Although a high proportion of donor leukocytes in 
the heart grafts correlated with the CR-free state, it did 
not predict the extent to which donor-specific nonreac-
tivirv had developed. The presence of a large percentage 
of donor leukocytes in the cell suspensions prepared 
from CR-free heart allografts in group 4 was clearly 
dependent on a once-weekly maintenance dose of 
T AC. When the weekly treatment was stopped at post-
transplantation day 27 (group 3), the incompleteness of 
the tolerance was quantifiable by the extent of CR; 
nevertheless, it was enough to allow such hearts co con-
sistently survive longer than 200 days.l! 
The poor correlation of donor cells in the allografts 
(and also in recipient tissues) with donor-specific non-
reactivity also was obvious at the low end of the donor 
leukocyte scale. The sparse donor leukocytes at 5 days 
in the highly durable hearts of the drug-free BMC-
primed recipients (group 5) were not distinguishable by 
the methods used in our study from those in the irre-
versibly rejecting allografts of the untreated group 2, 
underscoring the futility of equating arbitrary levels of 
chimerism with tolerance.46-49 
Differences in lineage profiles of the graft leukocytes 
did not correlate with outcome. However, several find-
ings were noteworthy. First, both donor and recipient 
leukocytes always were multilineage. Second, the deple-
tion of donor ED2+ cells (tissue macro phages) from the 
heart allografts was accelerated by priming (similar to 
analogous findings of Armstrong et al50), but it was 
markedly inhibited by immunosuppression. Third, do-
nor ED 1 + macrophages (monocytes/phagocytes) also 
were depleted in the 1 DO-day heart allografts of all ex-
perimental groups, but they were replaced by dispro-
portionate numbers of infiltrating ED 1 + host cells, 
consistent with previous claims that these macrophages 
are important effector cells in both acute rejection 
and CR.5 1-53 
Finally, the subpopulation of donor leukocytes in 
the allograft cell suspensions stained by the LEW MH C 
class II-specific L21-6 mAb and previously identified as 
DCS9,11,54,55 made up only a small fraction of the nu-
merous donor leukocytes contained in the CR-free car-
diac allografts of groups 4 and 6. However, when the 
donor cells were less than 3% orche total leukocytes, the 
L21-6+ cells made up the majority, raising the possibil-
ity that this tiny residual population of migratory cells 
had lost the ability to mount a GVH reaction, whereas 
selectively retaining the capacity of antigen presenta-
tion. This interpretation is consistent with the hypoth-
esis that periodic leakage of donor leukocytes from the 
nonlymphoid to the lymphoid compartment maintains 
stable-state clonal exhaustion-deletion4,29 similar to 
that in tolerant mouse-liver recipients56 and a model of 
autoimmune diabetes mellitus,57.58 
Whether they were present in large or small num-
bers, between half and two thirds of the L21-6+ cells in 
the 1 DO-day cell suspension expressed CD 11 bl c and 
were believed to be the classic mveloid DCs originally 
described by Steinman and Cohn.!3,!4 The remaining 
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nonmyeloid L21-6+ cells may have been DCs oflym-
phoid origin59 .60 or class II-expressing lymphocytes. 
Contrary to a current hypothesis,61 there was no corre-
lation between the percentage of the ostensible lym-
phoid DCs in the L21-6 T fraction and donor-specific 
nonreactivity. 
Collectively, the studies reported here indicate that 
the extent of CR defines the incompleteness of toler-
ance. Once initiated, the HVG and GVH immune 
responses can be terminated in 2 ways, both involving 
apoptosis. If 1 leukocyte population eliminates the 
other, its antigen-specific clonal expansion ceases, shut-
ting down the secretion of IL-2 and other molecules. 
The resulting passive apoptosis of the cytokine-defi-
cient clone requires new protein synthesis, is strongly 
inhibited by Bcl-2 and related antiapoptotic molecules 
(consistent with experiments by Hancock et al62), and is 
believed to involve mitochondrial apoptosis mecha-
nisms rather than such death cytokines as Fas ligand 
(FasL) and TNF (summarized by Lenardo et al63). 
When the alloantigen cannot be eliminated, the 
continuing response may be terminated by the so-called 
activation-associated clonal exhaustion-deletion, the 
seminal mechanism of acquired tolerance4.6.7 that has 
been shown in several nontransplant and transplant 
tolerance models.64-n Although this kind of apoptosis 
involves FasL and TNF and occurs by different molec-
ular pathways than those of antigen withdrawal,63 there 
is evidence that both kinds of apoptosis are in-
volved.73.74 Organ allografts develop CR if the MHC-
restricted HVG reaction becomes unrelenting when it 
is not terminated either by rejection of the allograft and 
its peripheralized leukocytes or by the induction of do-
nor-specific tolerance to a level less than the threshold 
for destructive immunity.4 Although nonimmunologic 
factors may contribute to the immunopathological 
characteristics of CR,75-79 evidence supporting a 
straightforword donor-specific HVG response as the 
core cause is overwhelming.8o.s4 
This pathogenesis explains very well why it has been 
so difficult in human organ recipients to achieve the 
closely related objectives of drug-free tolerance and free-
dom from CR. The prevention with immunosuppres-
sion of destructive immunity (i.e., rejection) for long 
enough to allow the variable induction of tolerance has 
been the sine qua non of clinical organ transplantation. 
Organ transplantation has flourished with minimal re-
liance on HLA matching more because of the advent of 
increasingly potent immunosuppressants than any 
other factor. However, because tolerance induction de-
pends on the acute clonal activation that is interdicted, 
the penalty may be the inability to ever stop drug ther-
apy.68,H5 If maintenance immunosuppression is re-
duced to less than the threshold necessary to comple-
ment the variably incomplete tolerance induced largely 
at the outset, CR ensues coincident with disappearance 
of the donor leukocytes from the host tissues and allo-
grafr.4,11 This chain of events was evident in our nai:ve 
heart recipients treated with T AC. T AC significantly 
reduced the immune reaction, judged by studies of 
costimulatory molecule expression, cytokine profiles of 
heart tissue extracts, in vivo test of host immune 
reactiviry, and apoptosis. The subsequent depen-
dence on immunosuppression to maintain a stable 
state was analogous to that in the vast majoriry of 
partially tolerant human recipients of long-surviving 
organ allografts. 
Clinical efforts to facilitate tolerance in organ recip-
ients with adjunct donor BMCs have been hampered by 
the need to administer the same potentially antitolero-
genic immunosuppression as that used for conventional 
organ transplantation. The low-level chimerism nor-
mally found in organ recipients has been increased 
many fold by the additional load of donor leukocytes 
and has been reported in some studies to result in a 
greater incidence of donor-specific nonreactivity.86-88 
However, discontinuance of immunosuppression has 
not been achieved. 
References 
1. Zinkemagel RM, Doherty Pc. Restriction of in vitro T celI-
mediated cytoroxicity in lymphocytic choriomeningitis within a 
syngeneic or semi-allogeneic system. Nature 1974;248:701-702. 
2. Doherty PC, Zinkemagel RM. A biological role for the major 
histocompatibility antigens. Lancet 1975; 1: 1406-1409. 
3. Zinkernagel RM, Doherty Pc. The discovety of MHC restric-
tion. Immunol Today 1997;18:14-17, 
4. 5tarzl TE, Zinkemagel ZR. Antigen localization and migration 
in immunity and tolerance. N Engl] Med 1998;339: 1905-1913, 
5. Statzl TE, Demettis A], Murase N, Ildstad S, Ricordi C, Trucco 
M. Cell migration, chimerism, and graft acceptance. Lancet 
1992;339: 1579-1582. 
6. Stanl TE, Demerris AJ, Trucco M, Ramos H, Zeevi A, Rudert 
WA, et a1. Systemic chimerism in human female recipients of 
male livers. Lancet 1992:340:876-877. 
7. Stanl TE, DemetrisAJ, Trucco M, Murase N, Ricordi C, Ildstad 
S, er a1. Cell migration and chimerism after whole-organ trans-
plantation: The basis of graft acceptance. Hepatology 1993; 17: 
1127-1152. 
8. Mutase N, Demetris AJ, WOO J, Tanabe M, Furuya T, Todo S, 
Starzl TE. Graft-versus-host disease (GYHD) after BN to LEW 
compared ro LEW to BN rat intestinal transplantation under FK 
506, Transplantation 1993;55: 1-7. 
9. Demetris AJ, Murase N, Fujisalci $, FungJJ, Rao AS, Starzl TE. 
Hematolymphoid cell trafficlcing, microchimerism, and GYH 
reactions after liver, bone marrow, and heart transplantation. 
Transplant Proc 1993;25:3337-3344, 
... 
700 Ichikawa et at 
10. Qian S. Demetris AJ. Murase N. Rao AS. Fung JJ. Starzl TE. 
Murine liver allograft transplantation: Tolerance and donor cell 
chimerism. Hepatology 1994;19:916-924. 
11. Murase N. Starzl TE. Tanabe M. Fujisaki S. Miyazawa H. Ye Q. 
et al. Variable chimerism. graft-versus-host disease. and tolerance 
after different kinds of cell and whole organ transplantation from 
Lewis to brown Norway rats. Transplantation 1995;60: 158-171. 
12. Terakura M. Murase N. Demetris AJ. Ye Q, Thomson A, Starzl 
TE. Lymphoid/non-lymphoid compartmentalization of donor 
leukocyte chimerism in rat recipients of heart allografts, with or 
without adjunct bone marrow. Transplantation 1998;66:350-
357. 
13. Steinman RM, Cohn ZA. Identification of a novel cell type in 
peripheral lymphoid organs of mice. l. Morphology. quantita-
tion, tissue distribution. J Exp Med 1973;137:1142-1162. 
14. Steinman RM. The dendritic cell system and its role in immu-
nogenicity. Ann Rev ImmunoI1991;9:271-296. 
15. Thomson AW, Lu L, Murase N, Demetris AJ. Rao AS, Starzl 
TE. Microchimerism, dendritic cell progenitors and transplan-
tation tolerance. Stem Cells 1995;13:622-639. 
16. DemetrisAJ, Murase N. Ye Q. Galvao FH, RichertC, Saad R. et 
al. Analysis of chronic rejection and obliterative arreriopathy. 
Possible contributions of donor antigen-presenting cells and 
lymphatic disruption. Am J Pathol 1997; 150:563-578. 
17. Gill TJD, Kunz HW. Misra ON. HassettAL. The major histo-
compatibility complex of the rat. Transplantation 1987;43:773-
785. 
18. Yagihashi A, Takahashi S, Murase N, Starzi TE, Iwaki Y. A 
monoclonal antibody (L21-6) recognizing an invariant chain 
expressed on the cell surface in rats with the exception of the BN 
(RTln): A study of tissue and strain distributions. Transplant 
Proc 1995;27:1519-152l. 
19. Dijkstra CD, Dopp EA,Joling P. Kraal G. The heterogeneiryof 
mononuclear phagocytes in lymphoid organs: Distinct macro-
phage subpopulations in the tat recognized by monoclonal anti-
bodies EDI. ED2. and ED3. Immunology 1985;54:589-599. 
20. Damoiseaux JG, Dopp EA. Calame W. Chao D. MacPherson 
GG, Dijkstra CD. Rat macrophage lysosomal membrane anti-
gen recognized by monoclonal antibody ED 1. Immunology 
1994;83:140-147. 
21. Barbe E, Damoiseaux JG, Dopp EA, Dijkstra CD. Characteriza-
tion and expression of the antigen present on resident rat mac-
rophages recognized by monoclonal antibody ED2. Immunobi-
ology 1990;182:88-99. 
22. Spencer Sc. Fabre JW. Characterization of the tissue macro-
phage and the interstitial dendritic cell as distinct leukocytes 
normally resident in the connective tissue of rat heart. J Exp Med 
1990;171: 1841-1851. 
23. Demetris A. Qian S. Sun H, FungJJ. Yagihashi A, Murase N. et 
al. Early events in liver allograft rejection: Delineation of sites of 
simultaneous intragraft and recipient lymphoid tissue sensitiza-
tion. Am J Pathol 1991; 138:609-618. 
24. Thomas JM, Contreras JL. Jiang XL, Eckhoff DE, Wang PX, 
Hubbard WJ, et aI. Peri transplant tolerance induction in ma-
caques: Early events reflecting the unique synergy between im-
munotoxin and deoxyspergualin. Transplantation 1999;68: 
1660-1673. 
25. Starzl TE, Demetris AJ. Murase N, Trucco M, Thomson AW, 
Rao AS. The lost chord: Microchimerism. Immunol Today 
1996:17:577-584. 
26. Ehl 5, Aichele P, Ramseier H. Barchet W, Hombach J, Pircher 
H. et aI. Antigen persistence and time of T-cell tolerization 
determine the efficacy of tolerization protocols for prevention of 
skin graft rejection. Nat Med 1998;4:1015-1019. 
27. Zinkernagel RM. Immunology taught by viruses. Science 1996; 
271:173-178. 
28. Zinkernagel RM, Ehl S. Aichele p, Oehen 5, Kundig T. Hen-
garrner H. Antigen localization regulates immune responses in a 
dose- and time-dependent fashion: A geographical view of im-
mune reactivity. Immunol Rev 1997; 156: 199-209. 
29. Zinkernagel RM, Hengarrner H. Antiviral immunity. Immunol 
Today 1997; 18:258-260. 
30. Zocchi MR, Poggi A, Rubartelli A. The RGD-containing do-
main of exogenous HIV-1 Tat inhibits the engulfment of apop-
toric bodies by dendritic cells. AIDS 1997;11:1227-1235. 
31. Albert ML, Sauter B. Bhardwaj N. Dendritic cells acquire anti-
gen from apoptotic cells and induce class I-restricted CTLs. 
Nature 1998;392:86-89. 
32. HuangFP. Platt N. Wykes M, MajorJR, Powell TJ,JenkinsCD, 
MacPherson GG. A discrete sub population of dendritic cells 
transports apoptotic intestinal epithelial cells to T cell areas of 
mesenteric lymph nodes. J Exp Med 2000;191:435-443. 
33. Sauter B, Albert ML, Francisco L. Larsson M, Somersan 5, 
Bhardwaj N. Consequences of cell death: Exposure to necrotic 
tumor cells, but not primary tissue cells or apoptotic cells, in-
duces the maturation ofimmunohistostimulatoty dendritic cells. 
J Exp Med 2000;191:423-433. 
34. Steinman RM. Turley S, Mellman I. Inaba K The induction of 
tolerance by dendritic cells that have captured apoptotic cells. J 
Exp Med 2000;191:411-416. 
35. Nemlander A. SOOts A. von Willebrand E, Husberg B. Hayry P. 
RediStribution of renal allograft-responding leukocytes during 
rejection. II. Kinetics and specilicity. J Exp Med 1982; 156: 1 087-
llOO. 
36. Larsen CPo Morris PJ, AusrynJM. Migration of dendritic leuko-
cytes from cardiac allografts into host spleens. A novel route for 
initiation of rejection. J Exp Med 1990;171:307-314. 
37. Bumgardner GL. Li J. Heininger M, Orosz CG. Costimulation 
pathways in host immune responses to allogeneic hepatocytes. 
Transplantation 1998;66:1841-1845. 
38. Bumgardner GL. Heininger M. LiJ. XiaD. Parker-ThornburgJ. 
Ferguson RM. Orosz CG. A functional model of hepatocyte 
transplantation for in vivo immunologic studies. T ransplanta-
tion 1998;65:53-61. 
39. Bumgardner GL, Li J. Heininger M, Ferguson RM, Orosz CG. 
In vivo immunogenicity of purified allogeneic hepatocytes in a 
murine hepatocyte transplant model. Transplantation 1998;65: 
47-52. 
40. Elkins WL, Guttmann RD. Pathogenesis of a local graft versus 
host reaction: Immunogenicity of circulating host leukocytes. 
Science 1968;159:1250-1251. 
41. Hayry p. von Willebrand E. Transplant aspiration cytology in 
the evaluation of a renal allograft. In: Touraine JL, Traeger J, 
Bemel H, Brochier J. DubernardJM. RevillardJP, Triau R (eds). 
Transplantation and clinical immunology, vol 15. Amsterdam: 
ExcerptaMedica, 1983:124-137. 
42. Forbes RD, Parfrey NA, Gomersall M, Darden AG, Guttmann 
RD. Dendritic cell-lymphoid cell aggregation and major histo-
compatibility antigen expression during rat cardiac allografr re-
jection. J Exp Med 1986;164:1239-1258. 
43. Sakamoto T, Ye Q. Lu L, Demetris A], Scarzl TE. Murase N. 
Donor hematopoietic progenitor cells in nonmyeloablated rat 
recipients of allogeneic bone marrow and liver grafts. T ransplan-
ration 1999;67:833-840. 
Donor and Recipient Leukocytes in Allografts 701 
44. O'Connell PJ, l\lba-Jonas A, Leverson GE, Heisey OM, Meyer 
KC, Love RE, Burlingham WJ. Stable lung allograft outcome 
correlates with the presence of intragraft donor-derived leuko-
cytes. Transplantation 1998;66: 11 67 -117 4. 
45. Burke CM. Theodore j, Dawkins KD, Yousem SA, Blank N, 
Billingham ME, et a1. Post-transplant obliterative bronchiolitis 
and other late lung sequelae in human heart-lung transplanta-
tion. Chest 1984;86:824-829. 
46. Wekerle T, Sykes M. Mixed chimerism as an approach for the 
induction of transplantation tolerance. Transplantation 1999; 
68:459-467 
47. Wren SM, Hronakes ML, lldstad ST. The requirement for allo-
geneic chimerism for second transfer of tolerance from mixed 
allogeneic chimeras (A+B->A) to secondary recipients. Trans-
plantation 1992;54:1031-1040. 
48. Bushell A, Pearson TC, Morris PJ, Wood KJ. Donor-recipient 
microchimerism and tolerance induction. Transplantation 
1996;61: 170-172. 
49. Wood K, Sachs DH. Chimerism and transplantation tolerance: 
Cause and effect. Immunol Today 1996;17:584-588. 
50. Armstrong HE, Bolton EM, McMillan I, Spencer SC, Bradley 
JA. Prolonged survival of actively enhanced rat renal allografts 
despite accderated cellular infiltration and rapid induction of 
both class I and class II MHC antigens. J Exp Med 1987;165: 
891-907. 
51. Paul LC, Grothman GT, Benediktsson H, Davidoff AL; Rozing 
J. Macrophage sub populations in normal and transplanted heart 
and kidney tissues in the rat. Transplantation 1992;53: 157-162. 
52. Cramer DV, Wu GO, Chapman FA, Gajulis E, Wang HK, 
Makowka L. Lymphocytic subsets and histopathologic changes 
associated with the development of hean transplant arterioscle-
rosis. J Heart Lung Transplant 1992;11:458-466. 
53. Adams DH, Wyner LR, Karnovsky MJ. Experimental graft ar-
teriosclerosis. II. Immunocytochemical analysis of lesion devel-
opment. Transplantation 1993;56:794-799. 
54. Murase]\;, Demerris AJ, WOO J, Furuya T, Nalesnik M, Tanabe 
M. et a1. Lymphocyte traffic and graft-versus-host disease after 
fully allogeneic small bowel transplantation. Transplant Proc 
1991 ;23:3246-3247. 
55. Demetris A], Murase N, Stanl TE. Donor dendritic cells after 
liver and heart allotransplantation under short-term immuno-
suppression. Lancet 1992;339: 161 O. 
56. Dahmen U, Qian S, Rao AS. Demetris AJ, Fu F, Sun H, et al. 
Split tolerance induced by orthotopic livet transplantation in 
mice. Transplantation 1994;58: 1-8. 
57. Ohashi PS, Oehen S. Buerki K, Pircher HP, Ohashi CT. Oder-
man B, et al. Ablation of "tolerance" and induction of diabetes 
by viruses infection in viral antigen transgenic mice. Cell 1991; 
65:305-317. 
58. Ohashi PS, Oehen S. Aichele P, Pircher H, Odermart B, Herrera 
P, et a1. Induction of diabetes is influenced by the infectious virus 
and local expression of MHC class I and tumor necrosis factor-a. 
J ImmunoI1993;150:5185-S194. 
59. Vremec 0, Zorbas M, Scollay R, Saunders OJ. Ardavin CF, Wu 
L, Shortman K. The surface phenotype of dendritic cells purified 
from mouse thymus and spleen: Investigation of the CDS ex-
pression bv a subpopulation of dendtitic cells. J Exp Med 1992: 
176:47-58. 
60. Shortman K, Vremec 0, Corcotan LM, Georgopoulos K, Lucas 
K, \'(Iu L. The linkage berween T-cell and dendritic cell develop-
ment in the mouse thymus. Immunol Rev 199;165:39-46. 
G 1. Fazekas de 5t Groth B. The evolution of self-tOlerance: A new cell 
arises to meet the challenge of self-reactivit)". Immunol Toda)' 
1998;19:448-454. 
62. Hancock 'Vl'W', Buelow R, Sayegh MH, T urka L. Anribody-
induced transplant arteriosclerosis is prevented by graft expres-
sion of anti-oxidant and anti-apoptotic genes. Nat Med 1998;4: 
1392-1396. 
63. Lenardo M. Chan FK, Hornung F, McFarland H, Siegel R, 
Wangj, Zheng L. Mature lymphocyte apoprosis-immune regu-
lation in a dynamic and unpredictable anrigen environment. 
Ann Rev Immunol 1999;17:221-253. 
64. Webb S, Morris C, Sprent J. Exrrathymic tOlerance of mature T 
cells: Clonal elimination as a consequence of immunity. Cell 
1990:63: 1249-1256. 
65. Moskophidis 0, Lechner F, Pircher H. Zinkernagel RM. Virus 
persistence in acurely infected immunocompetent mice by ex-
haustion of antiviral cytotoxic effector T cells. Nature 1993;362: 
758-761. 
66. Critchfield J, Racke M, Zuniga-Pflucker J. Cannella B, Raine 
CS, Goverman J, Lenardo MJ. T cell deletion in high antigen 
dose therapy of autoimmune encephalomyelitis. Science 1994; 
263:1139-1143. 
67. Aichele p, Brduscha-Riem K, Zinkernagel RM, Hengarrner H, 
Pircher H. T cell priming versus T cell tolerance induced by 
synthetic peptides. J Exp Med 1995;182:261-266. 
68. Bishop GA, Sun J, DeCruz OJ. Rokahr KL, SedgwickJD, Sheil 
AG, er al. Toletance to rat liver allografts. III. Donor cell migra-
tion and toletance-associated cytokine production in peripheral 
lymphoid tissues. J ImmunoI199G;156:492S-4931. 
69. Qian S, Lu L, Fu F, Li Y, Starzl TE, Fung n, Thomson AW. 
Apoptosis within spontaneously accepted mouse liver allografts: 
Evidence for deletion of cytotoxic T cells and implications for 
tolerance induction. J ImmunoI1997;158:4654-4661. 
70. Meyer 0, Baumgardt S, Loeffeler S, Czub S, Otto C, Gasse! HJ, 
et al. Apoptosis of T lymphocytes in liver and/or small bowel 
allografts during tolerance induction. Transplantation 1998;66: 
1530-1536. 
71. Wekerle T, Sayegh MH, Hill J, Zhao Y, Chandtaker A, Swenson 
KG, et aI. EJGtrathymic T cell deletion and allogeneic stem cell 
engraftment induced with costimulatory blockade is followed by 
central T cell tolerance. J Exp Med 1998;187:2037-2044. 
72. Lu L, Li W, Zhong C, Qian S, Fung n, Thomson A W, Starzl 
TE. Increased apoptosis of immunoreactive host cells and aug-
mented donor leukocyte chimerism, not sustained inhibition of 
B7 molecule expression are associated with prolonged cardiac 
allograft survival: In mice preconditioned with immature donor 
dendritic cells plus anti-CD40L mAb. Transplantation 1999;68: 
747-757. 
73. Li Y, Li Xc, Zheng XX, Wells AD, Turka LA, Strom TB. 
Blocking both signal 1 and signal 2 ofT-cell activation prevents 
apoptosis of alloreactive T cells and induction of peripheral allo-
graft wlerance. Nat Med 1999;5: 1298-1302. 
74. Wells AD, Li Xc, Li Y, Walsh Me. Zheng XX, Wu Z, et aJ. 
Requirement for T-cell apopwsis in the induction of periphetal 
transplantation tolerance. Nat Med 1999;5:1303-1307. 
75. Tilnev NL. Chronic rejection. In: Ginns LC. Cosimi AB, Morris 
PJ (eds). Transplantation. Malden: Blackwell Scientific, 1999: 
43-53, 56-58. 
76. Hayry P. Commentary on Tilney NL: Chronic rejection. In: 
Ginns LC, Cosimi AB, Morris PJ (eds). Transplantation. Mal-
den: Blackwell Scientific, 1999:53-59. 
77. Mackenzie HS, Tullius SG, Heemann UW, Azuma H, Rennke 
HG. Brenner BM, Tilne), NL. l\'ephron suppl" is a major deter-
702 Ichikawa et al 
minant oflong-term renal allografi: outcome. J Clin Invest 1994; 
94:2148-2152. 
78. Yilmaz S, Paavonen T, Hayry P. Chronic rejection of rat renal 
allografts. II. The impact of prolonged ischemia time on trans-
plant histology. Transplantation 1992;53:823-827. 
79. Chectow GM, Milford EL, Mackenzie HS, Brenner BM. Anti-
gen-independent determinants of cadaveric kidney transplant 
failure. JAMA 1996;276: 1732-1736. 
80. Cramer OV, Qian SQ, Harnaha J, Chapman FA, Estes LW, 
Starzl TE, Makowka L. Cardiac rransplantation in the rat. 1. The 
effect of histocompatibiliry differences on grafi: arteriosclerosis, 
Transplantation 1989;47:414-419, 
81, Hancock WH, Whirley WO, Tullius SG, Heemann UW, Wa-
sowska B, Baldwin WM III, Tilney NL. Cyrokines, adhesion 
molecules, and the pathogenesis of chronic rejection of rat renal 
allografts, Transplantation 1993;56:643-650. 
82. Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing-
Jensen T, Willett TA, Sayegh MH. Chronic cardiac rejection in 
the LEW to F344 rat model: Blockade of CD28-B7 costimula-
tion by CTLA4Ig modulates T cell and macrophage activarion 
and attenuates arteriosclerosis. J Clin Invest 1996;97:833-838. 
83. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter 
CB, Tilney NL, Sayegh MH. Blockade ofT cell costimulation 
prevents development of experimental chronic a1lografi: rejec-
tion. Proc Nat! Acad Sci USA 1996;93:12439-12444. 
84. Murphy B, Kim KS, Buelow R, Sayegh MH, Hancock WW. 
Synthetic MHC class I peptide prolongs cardiac survival and 
attenuates transplant arteriosclerosis in the Lewis-> Fischer 344 
model of chronic allografi: rejection. Transplantation 1997;64: 
14-19. 
85. Larsen CP, Elwood ET, Alexander OZ, Ritchie SC, Hendrix R, 
Tucker-Burden C, et al. Long-term acceptance of skin and car-
diac allografi:s afi:er blocking CD40 and C028 pathways. Nature 
1996;381 :434-438. 
86. Fontes P, Rao A, Oemetris AJ, Zeevi A. Trucco M, Carroll P, et 
al. Augmentation with bone marrow of donor leukocyte migra-
tion for kidney, liver, heart, and pancreas islet transplantation. 
Lancet 1994;344:151-155. 
87. Salgar S. Shapiro R, Dodson F. Corry R, McCurry K. Zeevi A. et 
a!. Infusion of donor leukocytes to induce tolerance in organ 
allografi: recipients. J Leukoc Bioi 1999;66:310-314. 
88. Garcia Morales R. Esquenazi V, Zucker K, Gomez CI. Fuller L. 
Carreno M, et a!. Assessment of the effects of cadaver donor bone 
marrow on kidney allografi: recipient blood cell chimerism by a 
novel technique combining PCR and flow cytometry (PCR-
FLO'ilG'). Transplantation 1996;62:1149-1160. 
